NCT02238925View on ClinicalTrials.gov

An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

January 31, 2016

Conditions
Acute Myeloid Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)Myelodysplastic Syndrome (MDS)
Interventions
DRUG

CPX-351

Trial Locations (5)

29425

Medical University of South Carolina, Charleston

46237

Franciscan Saint Francis Health, Indianapolis

53226

Medical College of Wisconsin, Milwaukee

66205

University of Kansas Cancer Center, Westwood

97239

Oregon Health & Science University, Portland

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY